Core Scientific AMD Deal: CORZ Price Outlook After Q2
2026-07-31
Core Scientific delivered two major pieces of news on the same morning, a landmark infrastructure partnership with AMD and a Q2 earnings report showing revenue more than doubling year over year, and the stock still couldn't hold onto its early gains.
Shares jumped as much as 10% in premarket trading before giving most of it back and closing lower on the day.
That kind of reaction, genuinely strong headline news met with investor skepticism, tells you a lot about where CORZ sits right now: mid-transformation, carrying real execution risk, and trading on a story Wall Street hasn't fully agreed on yet.
Key Takeaways
Core Scientific signed 15-year lease agreements with AMD covering roughly 530 megawatts across five sites, with more than $14 billion in potential contracted revenue and an option to expand to 2.5 gigawatts, though revenue doesn't begin until 2027.
Q2 2026 revenue reached $164.2 million, more than double the prior year, but Core Scientific posted a $1.16 billion net loss, driven almost entirely by a non-cash accounting charge tied to rising warrant values rather than operating losses.
CORZ initially popped as much as 10% on the news before reversing to close lower, largely on investor concerns about an undisclosed "neocloud" subtenant and the dilution overhang from 30 million AMD warrants, before analysts raised price targets the following day.
What Is the Core Scientific AMD Deal? Answer-First Definition
The Core Scientific AMD deal is a 15-year infrastructure agreement under which AMD will lease roughly 530 megawatts of U.S. data center capacity across five Core Scientific sites beginning in 2027, with an option to expand to 2.5 gigawatts, deploying AMD's Instinct GPUs, EPYC CPUs, and ROCm software, in exchange for warrants allowing AMD to purchase up to 30 million Core Scientific shares.
Core Scientific AMD Deal and Q2 2026 At a Glance
Inside the 2.5 Gigawatt AMD Capacity Agreement
The headline number, 2.5 gigawatts of potential leasable capacity, represents Core Scientific's full expansion ceiling with AMD, but the actual signed commitment is more specific.
The initial 530 megawatts breaks down into 377 megawatts leased directly to AMD across three sites, plus 152 megawatts, roughly 29% of the initial capacity, leased to an undisclosed "neocloud" tenant under a separate agreement with AMD providing credit support.
That undisclosed customer turned out to be a significant factor in how the market reacted to the news, more on that shortly.
Under the agreement, AMD will deploy its Instinct GPU accelerators, EPYC server processors, and ROCm software stack across the leased capacity, with both companies collaborating on the physical infrastructure design needed to support high-density AI workloads.
Revenue from these leases doesn't begin until 2027, meaning the deal represents a long runway of contracted future revenue rather than an immediate financial boost.
Read Also: Tesla Crashes 14% on Earnings Miss and Negative Free Cash Flow
AMD Stock Warrants Explained
As part of the arrangement, Core Scientific issued AMD warrants to purchase up to 30 million shares of CORZ common stock at $23.47 per share, a price that sat roughly 17% above Core Scientific's stock price at the time of signing.
Approximately 6.5 million of those warrants vested immediately upon signing the initial leases, with the remainder vesting sequentially as additional hosting capacity comes online.
Structuring the incentive this way limits immediate dilution while giving AMD a direct financial stake in Core Scientific's long-term success, but it also means existing shareholders face a real overhang: if CORZ shares appreciate well past the strike price, AMD's eventual exercise of those warrants will dilute the existing share count.
In Simple Terms
Warrants work a bit like stock options extended to a business partner instead of an employee. AMD gets the right, but not the obligation, to buy CORZ shares at a fixed price later, and that right becomes more valuable the higher Core Scientific's stock climbs.
It's a smart way to align incentives, AMD benefits more if the partnership succeeds and the stock rises, but it also means some of Core Scientific's future upside is effectively already spoken for.
That dynamic is a big part of why the stock's initial reaction to genuinely good news was muted rather than euphoric.
If you're weighing how to track a story like this alongside a broader portfolio, tokenized stock trading through a platform like Bitrue's TradFi offering lets you follow and act on names like CORZ from the same account you use for crypto.
Key Entities to Know
Core Scientific (CORZ): the Nasdaq-listed company pivoting from Bitcoin mining toward high-density AI colocation services, operating facilities across seven U.S. states.
AMD: the chipmaker securing long-term U.S. data center capacity through this deal to support its Instinct GPU and EPYC CPU AI infrastructure roadmap.
The undisclosed neocloud tenant: a separate customer leasing roughly 152 megawatts of the initial capacity under AMD-supported credit terms, whose anonymity became a focal point of investor concern.
Warrants: the financial instruments giving AMD the right to purchase up to 30 million CORZ shares at a fixed $23.47 strike price as capacity comes online.
Read Also: Alphabet Stock Drops 7% After Hiking 2026 Capex to $205 Billion
Core Scientific Q2 2026 Earnings: Revenue Growth vs. the Net Loss Headline
Source: investors.corescientific.com
Core Scientific's underlying growth numbers were genuinely strong. Total revenue reached $164.2 million, more than double the $78.6 million reported a year earlier and up from $115.2 million in Q1, beating analyst estimates near $135 million.
Colocation revenue, the core of the company's AI infrastructure pivot, jumped to $136.7 million from just $10.6 million a year prior, with colocation gross margin improving to 59% from 11% over that same span.
Adjusted EBITDA came in at $41.1 million, up sharply from $28.5 million a year earlier, and operating cash flow for the first half of 2026 was positive at $230.9 million.
Then there's the headline that likely spooked less careful readers: a $1.16 billion net loss for the quarter. It's important to understand what actually drove that number. Roughly $1.05 billion of it came from a non-cash change in the fair value of warrants and contingent value rights.
An accounting adjustment that increases as Core Scientific's stock price rises, meaning this "loss" is largely a function of the stock performing well, not the underlying business bleeding cash.
Stripping out that and other non-cash items is exactly what Adjusted EBITDA is designed to do, and that figure, positive and growing, tells a very different story than the GAAP net loss headline alone.
Read also: A guide to trading TradFi assets on Bitrue
CORZ Stock Reaction: Why Good News Didn't Immediately Pop the Stock
Shares jumped as much as 10% in premarket trading on the news before reversing to close down roughly 2.7% to 4% on the day.
AMD stock fell as well, down between 4% and 6.6%, though Reuters noted that decline mirrored broader softness across chipmakers rather than reflecting anything specific to the Core Scientific deal.
Two concerns drove the reversal in CORZ shares. First, that undisclosed neocloud tenant leasing nearly 29% of the initial capacity introduced uncertainty investors weren't fully comfortable pricing in, an unnamed counterparty's credit quality and business durability are harder to underwrite than a household name like AMD.
Second, the scale of the AMD warrant grant, up to 30 million shares against roughly 320 million shares outstanding, highlighted a meaningful dilution overhang that tempered enthusiasm for the headline $14 billion figure.
Sentiment shifted again the following day. Needham & Company reiterated its Buy rating and $29 price target, calling the AMD agreement a "large quality lease" and attributing the prior day's weakness to broader AI infrastructure sector selling rather than deal-specific concerns.
Canaccord also raised its price target, framing the deal as validation of Core Scientific's AI strategy following the company's earlier decision to end exclusive talks with another prospective hyperscaler partner.
Is CORZ Overvalued After the Deal?
That depends heavily on which side of the story you weight more. The bull case rests on real, verifiable momentum: colocation revenue up more than twelvefold year over year, total company leased capacity now at roughly 1.1 gigawatts representing over $24 billion in potential contracted revenue, positive operating cash flow, and a growing, diversifying customer roster beyond any single hyperscaler relationship.
Needham's $29 target is built on 19 times the firm's discounted estimate of 2027 adjusted EBITDA, reflecting confidence the AI colocation transition is executing on schedule.
The bear case centers on execution and balance sheet risk. Long-term debt jumped to roughly $4.3 billion from about $1.06 billion the prior quarter as Core Scientific issued new debt to fund its buildout, a significant increase in financial leverage.
Revenue from the AMD leases doesn't begin until 2027, leaving construction, permitting, power availability, and customer credit risk all still ahead of the company.
And the 30 million share warrant grant represents real potential dilution if the stock performs well enough for AMD to exercise it broadly.
This isn't financial advice, and given the stock's volatility, roughly 40 to 50% swings over recent months, careful position sizing matters more than trying to call a precise entry point.
Read Also: Meta Reports July 29 Near Record Highs: AI Capex in Focus
Common Mistakes When Reading This Story
Treating the $1.16 billion net loss as an operating cash crisis. The bulk of that figure came from a non-cash warrant valuation adjustment tied to Core Scientific's rising stock price, not from the underlying business losing money.
Assuming the full $14 billion in potential revenue is guaranteed. These are 15-year potential contracted revenue figures dependent on construction timelines, customer credit, and successful execution through 2027 and beyond.
Overlooking the undisclosed neocloud tenant's role. Nearly 29% of the initial capacity rests on an unnamed counterparty, a genuine source of uncertainty distinct from the AMD relationship itself.
Ignoring the new debt load. Long-term debt roughly quadrupled quarter over quarter to fund the buildout, a real balance sheet shift worth tracking alongside the growth headlines.
Reading the premarket pop as the market's final verdict. CORZ's initial 10% premarket gain reversed within the same session, showing how quickly sentiment can shift once investors dig into deal specifics.
Interpretation Cheat Sheet
Expert Summary
Core Scientific's AMD deal and Q2 results together tell a coherent story of a company genuinely transforming from Bitcoin mining into AI infrastructure, backed by real revenue growth, improving margins, and a rapidly expanding contracted backlog.
The market's initial hesitation wasn't really about doubting that transformation, it was about pricing in the specific risks layered on top of it: an unnamed subtenant, a meaningful dilution overhang, and a dramatically larger debt load funding a buildout that won't generate AMD-related revenue until 2027.
Whether CORZ is overvalued from here likely depends less on the headline $14 billion figure and more on how cleanly the company executes construction and lease commencement over the next 18 months.
Want to track CORZ and other AI infrastructure names alongside your crypto portfolio? Register a free Bitrue account to get started with Bitrue's TradFi trading platform.
Bitrue's guide to trading TradFi assets explains how the feature works, and its roundup of tokenized US stocks covers which names are currently available.
FAQ
What did Core Scientific and AMD actually agree to?
Core Scientific signed 15-year leases with AMD covering approximately 530 megawatts of U.S. data center capacity across five sites, with an option to expand to 2.5 gigawatts, representing more than $14 billion in potential contracted revenue starting in 2027.
Why did Core Scientific report a $1.16 billion net loss despite strong revenue growth?
The vast majority of that loss, roughly $1.05 billion, came from a non-cash accounting adjustment reflecting the rising fair value of warrants tied to Core Scientific's stock price appreciation, not from operating losses in the underlying business.
Why did CORZ stock fall after announcing the AMD deal?
Shares reversed an initial premarket gain due to investor concerns about an undisclosed "neocloud" tenant leasing nearly 29% of the initial capacity, and the dilution overhang from warrants allowing AMD to purchase up to 30 million CORZ shares.
Is Core Scientific still involved in Bitcoin mining?
Core Scientific still holds a small Bitcoin position, around 848 BTC as of recent disclosures, but is actively repurposing its remaining mining facilities toward AI colocation services and recently terminated a chip-purchase agreement tied to its mining business.
What is Core Scientific's total contracted revenue potential across all customers?
Including the AMD deal and existing customers, Core Scientific's total leased customer power capacity reached roughly 1.1 gigawatts as of Q2 2026, representing more than $24 billion in potential contracted revenue.
Disclaimer: The views expressed belong exclusively to the author and do not reflect the views of this platform. This platform and its affiliates disclaim any responsibility for the accuracy or suitability of the information provided. It is for informational purposes only and not intended as financial or investment advice.
Disclaimer: The content of this article does not constitute financial or investment advice.
